943001-56-7
Chemical Structure
Tigilanol tiglate
Synonym(s): EBC-46
- CAS No.: 943001-56-7
- Formula:C30H42O10
- Molecular Weight:562.65
IUPAC Name: (1aR,1bR,1cS,2aR,3S,3aS,6aS,6bR,7R,8R,8aS)-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-8a-(((S)-2-methylbutanoyl)oxy)-4-oxo-1a,1b,1c,2a,3,3a,4,6a,6b,7,8,8a-dodecahydro-1H-cyclopropa[5',6']benzo[1',2':7,8]azuleno[5,6-b]oxiren-8-yl (E)-2-methylbut-2-enoate
InChIKey: YLQZMOUMDYVSQR-FOWZUWBHSA-N
SMILES: CC[C@H](C)C(O[C@@]12[C@@]([C@]3([H])[C@@]4([H])[C@](O4)([C@H]([C@]5([C@](C=C(C5=O)C)([H])[C@]3([C@@H]([C@H]2OC(/C(C)=C/C)=O)C)O)O)O)CO)([H])C1(C)C)=O
Biological Activity: Tigilanol tiglate (EBC-46) is a protein kinase C (PKC)/C1 domain activator. Tigilanol tiglate is associated with mitochondrial/endoplasmic reticulum (ER) dysfunction, leading to activation of the unfolded protein response (UPRmt/ER) and subsequent induction of ATP depletion, organelles expansion, Caspase activation, gasdermin E cleavage, and terminal necrosis. Tigilanol tiglate, as a small anti-tumor molecule with immunomodulatory effects, can be used in the study of head and neck squamous cell carcinoma and soft tissue sarcoma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tigilanol tiglate | 96.35% | Tigilanol tiglate (EBC-46) is a protein kinase C (PKC)/C1 domain activator. Tigilanol tiglate is associated with mitochondrial/endoplasmic reticulum (ER) dysfunction, leading to activation of the unfolded protein response (UPRmt/ER) and subsequent induction of ATP depletion, organelles expansion, Caspase activation, gasdermin E cleavage, and terminal necrosis. Tigilanol tiglate, as a small anti-tumor molecule with immunomodulatory effects, can be used in the study of head and neck squamous cell carcinoma and soft tissue sarcoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Cullen J K, et al. Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade[J]. Journal for ImmunoTherapy of Cancer, 2024, 12(4). [Content Brief]
- [2]. Miller J, et al. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors. Front Vet Sci. 2019 Apr 9;6:106. [Content Brief]
- [3]. Antwi FD, et al. Tigilanol Tiglate-Induced Changes in Secretome Profiles Alter C-Met Phosphorylation and Cell Surface Protein Expression in H357 Head and Neck Cancer Cells. Cells. 2024 Jun 5;13(11):982. [Content Brief]
